Introduction
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (MPNs) characterized by clonal expansion of an abnormal hematopoietic stem/progenitor cell. 1 Understanding of the pathophysiology of these disorders dramatically improved following the description, in the last 3 years, of recurrent molecular abnormalities. These are represented by: the V617F mutation in JAK2 exon 14, [2] [3] [4] [5] that is the most frequent and involves 495% of PV and 60-70% of ET patients; a number of molecular alterations located in JAK2 exon 12, 6 that have been described in 50-80% of the JAK2 wild-type PV patients; 7, 8 mutations in MPL, 9,10 mostly represented by the W515L or W515K allele, that are presented by 7-8% of ET patients. Genotyping for such molecular abnormalities has already become a standard tool in the diagnostic work up of patients suspected to have an MPN and constitutes a major criterion for diagnosis, according to the proposed new WHO classification of myeloid neoplasms. 11 Recommendations for management of PV and ET are based on a limited number of randomized clinical trials performed within national or international collaborative groups and summarized in Tables 1 and 2 . In addition, several observational studies described the clinical course of the diseases and indirectly evaluated the role of different treatments. Thus, sound methodological evidence is limited and clinical expertise still plays a major role to guide therapy in these diseases. 22, 23 In practice, the first step to approach an individual patient with PV or ET is to identify the potential risk to develop major thrombotic or hemorrhagic complications. Then, treatment should be stratified with the aim to focus chemotherapy on high-risk patients. In this paper we review the current evidence and give our recommendations on the risk stratification and optimal treatment of patients with PV and ET.
Risk stratification

Evidence
The largest prospective study evaluating risk factors for survival and thrombosis in PV is the European Collaboration on Lowdose Aspirin in Polycythemia (ECLAP). 24 In this cohort of 1638 patients, the incidence of cardiovascular complications was higher in those aged more than 65 years (5.0% patient-year, hazard ratio (HR) 2.0, 95% confidence interval (CI) 1.22-3.29, Po0.006) or with a history of thrombosis (4.93% patient-year, HR 1.96, 95% CI 1.29-2.97, P ¼ 0.0017) than in younger subjects with no history of thrombosis (2.5% patientyear, reference category). These two variables were associated with an increased rate of vascular complications also in other large studies in ET (Table 3) . Other potential determinants of thrombotic risk, including cardiovascular risk factors (that is, smoking, hypertension, hypercholesterolemia, diabetes mellitus) or the presence of thrombophilic conditions, are more contentious.
ECLAP and several prospective studies in ET (summarized in Table 3 ) failed to show a clear association between platelet count and thrombotic events. Paradoxically, very high platelet counts can induce a bleeding tendency, mainly due to an acquired von Willebrand's disease. 37 An analysis of 99 young patients (aged o60 years) who presented with platelet count 41000 Â 10 9 per liter and without thrombohemorrhagic complications showed similar rates of major thrombosis and hemorrhage whether or not prophylactic cytoreductive therapy was given. 38 This study questions the practice to recommend cytoreduction in this category of patients.
At variance, leukocytosis was found to be an independent risk factor for thrombosis and survival both in PV and ET. Time-dependent multivariate analysis, adjusted for potential confounders including cytoreductive and antithrombotic treatment, showed that patients participating in the ECLAP study with a leukocyte count greater than 15 Â 10 9 per liter had a significant increase in the risk of thrombosis when compared to patients with leukocyte lower than 10 Â 10 9 per liter (HR 1.71, 95% CI 1.1-2.6), mainly due to an higher rate of myocardial infarction (HR 2.84, 95% CI 1.25-6.46, P ¼ 0.01). 39 Gangat et al. 40 also showed that leukocyte count 415 Â 10 9 per liter was an independent predictor of inferior survival, leukemic transformation and venous thrombosis in patients with PV. Three large cohort studies in ET reported that an increased baseline leukocyte count is a novel independent risk factor for both thrombosis and inferior survival. 30, 31, 41 In addition, Carobbio et al. 42 have recently demonstrated that 'low-risk' ET patients (that is, below 60 years and without previous thrombosis) with leukocytosis have the same probability to develop a vascular event in the follow-up of 'high-risk' patients without leukocytosis. Recent results have provided additional findings to support these clinical observations. In ET and PV, an in vivo leukocyte activation has been consistently documented, in association with signs of activation of both platelets and endothelial cells, particularly in patients carrying the V617F JAK2 mutation. [43] [44] [45] Thus, leukocyte and platelet activation may play a role in the generation of the prethrombotic state that characterizes these disorders.
Recently, the influence of the JAK2 V617F mutational load on the thrombotic risk has been evaluated in 173 patients with PV. 46 As compared to those with less than 25% mutant allele, patients harboring greater than 75% JAK2 V617F allele were at higher relative risk to develop major cardiovascular events during follow-up (relative risk (RR) 7.1, P ¼ 0.003). A trend towards more thrombotic events in 105 PV patients having greater than 80% mutant allele has also been reported by Silver et al. 47 On the other hand, Tefferi et al. 48 measured V617F allele burden in bone marrow-derived DNA obtained from 103 PV patients at variable times after diagnosis, and found that it was not correlated with major cardiovascular events. In ET, the presence of the V617F JAK2 mutation in about 60% of patients raised the question whether mutated and nonmutated patients 
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Leukemia SPOTLIGHT differ in terms of thrombotic risk. The largest prospective study on 806 patients suggested that JAK2 mutation in ET was associated with venous but not arterial events. 49 An increased risk of thrombosis in JAK2 mutated patients was retrospectively observed by other investigators. 50, 51 However, the rate of vascular complications was not affected by the presence of the mutation in two relatively large retrospective studies, including 150 and 130 ET patients, respectively. 52, 53 It is possible that the higher age distribution, hematocrit (HCT) and leukocyte levels consistently found in mutation-positive patients contributed to the apparent association between JAK2 V617F and thrombosis reported in some studies. A direct correlation of V617F allele burden with venous thrombosis in the follow-up has been reported by Kittur et al. 54 in 96 mutant patients with ET. On the other hand, in the largest series in ET from Antonioli et al., 55 that included 165 mutant patients, a V617F allele burden greater than 25% was associated with a relative risk of arterial thrombosis at diagnosis of 3.0 (95% CI 1.3-6.8) in multivariate analysis. A comprehensive review of the clinical correlates of JAK2 V617F presence or allele burden in MPNs has been recently published. 56 
Recommendations
By incorporating this body of knowledge in a clinically oriented scheme (Table 4) , patients with either PV or ET can be stratified in 'high-risk' or 'low-risk' categories according to their age and previous history of thrombosis; an 'intermediate-risk' category, that would include younger patients with coexisting generic cardiovascular risk factors in the absence of previous thrombosis, is also defined, but formal proof of its relevance to stratify patients is still lacking.
Extreme thrombocytosis (greater than 1.5 million per cubic millimeter) is considered a risk factor for bleeding rather than thrombosis, if any. Finally, putative novel variables, such as leukocytosis and JAK2V617F mutational status, might be incorporated in the risk classification, possibly allowing better definition of the low-risk group, once they have been eventually validated in prospective studies.
Treatment of low-risk patients
Evidence Phlebotomy. The only randomized study comparing phlebotomy with myelosuppressive therapy was done by the Polycythemia Vera Study Group (PVSG) more than 20 years ago (01 trial). 12 Patients treated in the phlebotomy arm had a better overall median survival at 13.9 years than the other two arms (chlorambucil, 8.9 years; radiophosphorus, 11.8 years) due to a reduced incidence of acute leukemia and other malignancies, albeit an excess of thrombosis was observed in phlebotomized patients during the first 3 years of treatment. In the PVSG-01 trial, the target HCT was set at 45% and this was based on old studies that showed in univariate analysis a correlation between thrombosis and HCT. 57 In the ECLAP study, despite the recommendation of maintaining the HCT values at less than 0.45, only 48% of patients had values below this threshold, whereas 39 and 13% of patients remained between 0.45 and 0.50 and greater than 0.50, respectively. However, a multivariate analysis considering all the confounders failed to show any correlation between these HCT values and thrombosis. 58 Low-dose aspirin. The efficacy and safety of low-dose aspirin (100 mg daily) in PV has been assessed in the ECLAP double-blind, placebo-controlled, randomized clinical trial. 18 This study randomized 532 PV patients to receive 100 mg aspirin or placebo. After a follow-up of about 3 years, data analysis showed a significant reduction of a primary combined end point including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and major venous thromboembolism (RR 0.4, 95% CI 0.18-0.91, P ¼ 0.0277). Major bleeding was not significantly increased by aspirin (RR 1.6, 95% CI 0.27-9.71).
In ET, aspirin at different doses (30-500 mg per day) has been found to control microvascular symptoms, such as erythromelalgia, and transient neurological and ocular disturbances including dysarthria, hemiparesis, scintillating scotomas, amaurosis fugax, migraine and seizures. 59 Translating evidence Abbreviations: ASA, aspirin; HU, hydroxyurea; n.s., not significant. a Plus ASA in 70% of patients in both groups.
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In the PT-1 randomized study comparing hydroxyurea (HU) vs anagrelide in high-risk patients with ET, discussed in detail below, 20 low-dose aspirin was given to both groups. An increased rate of major bleeding was registered in the anagrelide plus aspirin arm and this may be due to a synergistic effect of the two drugs on platelet function inhibition. 60 
Recommendations
All patients with PV are managed with phlebotomy and lowdose aspirin. For the time being, the recommended HCT target is below 45%, but the uncertainty described above prompted Italian Investigators to launch a prospective, randomized clinical study (CYTO-PV) addressing the issue of the optimal target of cytoreduction in PV (EudraCT 2007-006694-91).
ET patients at low risk for major vascular complications are left untreated. Aspirin is given in the presence of microvascular disturbances at the usual dose of 100 mg daily. Higher doses, up to 500 mg daily, may be necessary in the acute phase of erythromelalgia. A careful correction Table 3 Cohort 
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of concomitant cardiovascular risk factors should be pursued.
Pregnancy is a challenging event in young ET (and, less frequently, PV) women. However, no controlled studies addressing the management of pregnancy in ET have been published and current recommendation are based on pooled data from small-sized cohorts of patients and clinical expertise. 61 Interestingly, a recent study showed that JAK2 V617F is an independent predictor of pregnancy complications and that aspirin did not prevent complications in mutated patients and appear to worsen outcome in patients without the mutation. 62 Our management of pregnancy in MPNs is summarized in Table 5 .
Treatment of high-risk patients
Evidence Hydroxyurea. The first group of investigators who studied HU in the management of PV was the PVSG. HU is an antimetabolite that prevents DNA synthesis and, at that time, it was assumed to be not leukemogenic. In a paper summarizing their long-term experience with HU in 51 patients followed for a median of 8.6 years, the PVSG reported an incidence of leukemia of 9.8% (vs 3.7% in the historical phlebotomized controls) but less myelofibrosis (7.8 vs 12.7%) and fewer total deaths (39.2 vs 55.2%). 63 In the ECLAP study, HU alone was not found to enhance the risk of leukemia in comparison with patients treated with phlebotomy only (HR 0.86, 95% CI 0.26-2.88; P ¼ 0.8). However, the risk was significantly increased by exposure to radiophosphorus, busulphan or pipobroman (HR 5.46, 95% CI 1.84-16.25, P ¼ 0.002). The use of HU in patients already treated with alkylating agents or radiophosphorus also enhanced the leukemic risk (HR 7.58, 95% CI 1.85-31, P ¼ 0.0048). 64 A similar trend was observed by Gangat et al. 40 who reported a rate of acute myeloid leukemia of 2.4, 4, 11.6 and 16.7% in PV patients given no chemotherapy, HU only, other single cytotoxic drugs only and two or more cytotoxic agents, respectively. Two studies did not find significant differences in the rate of leukemic transformation in PV patients treated with HU or pipobroman, an alkylating agent with a mechanism of action that also involves metabolic competition with pyrimidine basis. 15, 65 HU has emerged as the treatment of choice also in high-risk patients with ET because of its efficacy and only rare acute toxicity. The efficacy of HU in preventing thrombosis in highrisk ET patients was demonstrated in a seminal randomized clinical trial. 19 A total of 114 patients were randomized to long-term treatment with HU (n ¼ 56) or to no cytoreductive treatment (n ¼ 58). During a median follow-up of 27 months, two thromboses were recorded in the HU-treated group (1.6% patient-year) compared with 14 in the control group (10.7% patient-year; P ¼ 0.003). Some long-term follow-up studies revealed that a proportion of ET patients treated with HU developed acute leukemia, particularly when given before or after alkylating agents or radiophosphorus. 66, 67 In other studies, however, the use of this drug as the only cytotoxic treatment was rarely associated with secondary malignancies; in an analysis of 25 ET patients younger than 50 years and treated with HU alone for a high risk of thrombosis, no case of leukemic or neoplastic transformation occurred after a median follow-up of 8 years (range 5-14 years). 68 In two other large studies, no significant association between HU and leukemic transformation was found. 41, 65 Interferon-a. Interferon-a (IFN-a) was considered for the treatment of patients with MPNs because this agent suppresses the proliferation of hematopoietic progenitors, has a direct inhibiting effect on bone marrow fibroblast progenitor cells, and antagonizes the action of platelet-derived growth factor, transforming growth factor-b and other cytokines, which may be involved in the development of myelofibrosis. 69 Published reports concern small consecutive series of patients in whom hematological response and side effects were evaluated. One review analyzed the cumulative experience with IFN-a in 279 patients with PV from 16 studies. 70 Overall responses were 50% for reduction of HCT to less than 0.45% without concomitant phlebotomies, 77% for reduction in spleen size and 75% for reduction of pruritus. In a recent review article, Silver 71 updated his experience on the long term use (median 13 years) of IFN-a in 55 patients with PV. Complete responses, defined by phlebotomy free, HCT less than 45% and platelet number below 600 Â 10 9 per liter, were reached in the great majority of cases after 1-2 years of treatment and the maintenance dose could be decreased in half of the patients. Noteworthy is the absence of thrombohemorrhagic events during this long follow-up.
IFN-a have been also used in ET patients. The results of several cohort studies, reviewed in Lengfelder et al., 72 indicate that reduction of platelet count below 600 Â 10 9 per liter can be obtained in about 90% of cases after about 3 months with an average dose of three million IU daily. IFN-a is not known to be teratogenic and does not cross the placenta. Thus, it has been used successfully throughout pregnancy in some ET patients with no adverse fetal or maternal outcome. 61 The main problem with IFN-a therapy, apart from its costs and parental route of administration, is the incidence of side effects. Fever and flu-like symptoms are experienced by most patients and usually require treatment with paracetamol. Signs of chronic IFN-a toxicity, such as weakness, myalgia, weight and hair loss, severe depression and gastrointestinal and cardiovascular symptoms, make it necessary to discontinue the drug in about one-third of patients. 70, 72 Pegylated forms of IFN-a allow weekly administration and potentially improve compliance. In a multicenter phase II trial of Table 5 Recommendations for management of pregnancy in MPN Severe pregnancy complications: X3 first-trimester or X1 second or third-trimester losses, birth weight o5th centile of gestation, pre-eclampsia, intrauterine death or stillbirth.
In one study 62 the presence of JAK2 V617F mutation increased the risk of pregnancy complications.
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Peg-IFN-a2a in 27 PV patients, Kiladjian et al. 73 showed a decrease of JAK2 mutant expression in 24 cases (89%) and in 1 patient mutant JAK2 was no longer detectable after 12 months of therapy. More limited effects on JAK2 mutational status have been reported after Peg-IFN-a2b therapy in a small group of patients with PV and ET. 74 Anagrelide. Anagrelide, a member of the imidazoquinazolin compounds, has a potent platelet-reducing activity devoid of leukemogenic potential and appeared to be the option to HU for reducing platelet counts in younger ET patients at high risk for thrombosis. The largest analysis reported so far comprised 3660 patients (2251 with ET). 75 With maximum follow-up of 7 years, anagrelide achieved platelet control in over 75% of patients and did not increase the conversion to acute leukemia (AL). However, other complications of the drug include palpitations, congestive heart failure, headache and depression.
HU and anagrelide (plus aspirin in both groups) have been compared head to head in a randomized clinical trial including 809 ET patients. 20 Patients in the Anagrelide arm showed an increased rate of arterial thrombosis (odds ratio (OR) 2.16, 95% CI 1.04-2.37, P ¼ 0.03), major bleeding (OR 2.61, CI 1.27-5.33, P ¼ 0.008) and myelofibrotic transformation (OR 2.92, CI 1.24-6.86, P ¼ 0.01) but a decreased incidence of venous thrombosis (OR 0.27, CI 0.11-0.71, P ¼ 0.006) compared to HU. In addition, Anagrelide was more poorly tolerated than HU and presented significantly greater rates of cardiovascular (Po0.0001), gastrointestinal (Po0.02), neurological (Po0001) and constitutional (Po0.001) side effects. Transformation to AL was comparable between the two arms (4 anagrelide vs 6 HU) although the small number of transformations and short followup prevented firm conclusions about leukemogenicity.
The results of a noninferiority randomized clinical trial comparing anagrelide to HU in 258 high-risk ET patients diagnosed according to the WHO classification have been reported in abstract form. 21 During the study period of 12 months, no differences were observed between the two arms with regard to the platelet-lowering effect, ET-related symptoms and rate of major thrombohemorrhagic complications, adverse effects and withdrawals.
Recommendations
In the risk/benefit profile evaluation, HU remains the first choice drug for most PV and ET patients requiring a cytoreductive therapy because it is the only treatment proven to be effective in reducing life-threatening thrombotic complications. The bulk of evidence does not attribute to HU a definite leukemogenic risk and whether AL is part of the natural history of MPNs or is a consequence of therapy is still a matter of debate. It is wise to adopt a cautionary principle and to consider carefully the use of this agent in young subjects and in those previously treated with other myelosuppressive agents or carrying cytogenetic abnormalities.
IFN-a and anagrelide are considered in special clinical settings, such younger patients, pregnancy (for IFN-a) and in cases resistant or intolerant to HU. 76 Our current recommendations for treatment of PV and ET patients are shown in Figures 1 and 2 .
JAK2 mutation as target of therapy
The demonstration that the V617F JAK2 plays a pivotal role in the pathogenesis of a large proportion of patients with MPN generated great interest in developing small molecule inhibitors specific to this mutation.
A series of JAK2 V617F inhibitors with promising potency and pharmaceutical properties for utility in the therapy of MPNs have been recently developed. [77] [78] [79] [80] [81] [82] [83] Preliminary data indicate that at least some of these small molecules inhibit cell growth that is dependent on constitutive JAK2/STAT signaling, preferentially suppress growth of progenitors carrying JAK-activating mutations and show significant clinical activity. Thus, these drugs hold promise as molecularly targeted agents for the therapy of patients with MPNs. High clinical risk and high mutation burden are probably the most important characteristics of the patients candidate for being included in phase II clinical studies. Indications for the use of these new drugs are critically dependent on their expected hematological and extra-hematological toxicity. JAK2 inhibitors with limited side effects, such as ITF2357, a histone deacetylase inhibitor, 78 can be proposed for patients with PV and/or ET provided they need therapy. However, more toxic agents should be reserved for patients with intermediate or high-risk primary and post-PV/ET myelofibrosis, given the significant disease-related morbidity and the poor prognosis in this setting. 84 
Phlebotom y Aspirin
Hydroxyurea Figure 1 Flowchart of therapeutic recommendations in polycythemia vera.
Hydroxyurea (HU)
Low-dose aspirin Figure 2 Flowchart of therapeutic recommendations in essential thrombocythemia.
Management of PV and ET G Finazzi and T Barbui 1499
Leukemia SPOTLIGHT
